|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Investment securities available for sale | ||||||||||||||||||||
| Restricted equity securities | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Cash value of life insurance | ||||||||||||||||||||
| Other real estate owned | ||||||||||||||||||||
| Properties and equipment, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Core deposit intangible | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Fed funds purchased | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Preferred stock, no par value; 5,000,000 shares authorized, none issued | ||||||||||||||||||||
| Common stock, no par value; 25,000,000 shares authorized, 5,672,204 and 5,666,204 issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Equity, Attributable to Parent | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
Loading...
